News
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the ...
ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the first-in-class monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback